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receptors, enhanced inhibitory
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SUMMARY

The fidelity of inhibitory neurotransmission is dependent on the accumulation of g-aminobutyric acid
type A receptors (GABAARs) at the appropriate synaptic sites. Synaptic GABAARs are constructed
from a(1-3), b(1-3), and g2 subunits, and neurons
can target these subtypes to specific synapses.
Here, we identify a 15-amino acid inhibitory synapse
targeting motif (ISTM) within the a2 subunit that promotes the association between GABAARs and the
inhibitory scaffold proteins collybistin and gephyrin.
Using mice in which the ISTM has been introduced
into the a1 subunit (Gabra1-2 mice), we show that
the ISTM is critical for axo-axonic synapse formation,
the efficacy of GABAergic neurotransmission, and
seizure sensitivity. The Gabra1-2 mutation rescues
seizure-induced lethality in Gabra2-1 mice, which
lack axo-axonic synapses due to the deletion of the
ISTM from the a2 subunit. Taken together, our data
demonstrate that the ISTM plays a critical role in
promoting inhibitory synapse formation, both in the
axonic and somatodendritic compartments.
INTRODUCTION
Brain function in the mammalian nervous system depends on a
dynamic relationship between excitatory and inhibitory neurotransmission (Fritschy, 2008; Selten et al., 2018). Inhibitory interneurons precisely control the firing of excitatory pyramidal
neurons and thus regulate network activity patterns (Roux and
Buzsáki, 2015). Interneurons inhibit the activity of pyramidal cells
by releasing the neurotransmitter g-aminobutyric acid (GABA)
onto synapses containing GABA type A receptors (GABAARs).
GABAARs are heteropentameric, ligand-gated ion channels
permeable to chloride. GABAARs can be composed from 19

different subunits, but synaptic GABAARs are understood to be
primarily assembled from 2 a(1-3), 2 b(1-3), and 1 g2 subunits
(Olsen and Sieghart, 2008; Sigel and Steinmann, 2012). Although
the structure of these subunits is highly conserved, the specific
combination of subunits in a given GABAAR does confer distinct
physiological and pharmacological properties on the receptor
(Goldstein et al., 2002; Rudolph et al., 1999). Subunit types are
also differentially localized within the neuron. For example,
GABAARs containing the a1 subunit tend to be found in dendritic
synapses, while those containing a2 are highly enriched in axoaxonic synapses at the axon initial segment (AIS) (Klausberger
et al., 2002; Nusser et al. 1996; Nyı́ri et al. 2001), the site of action
potential (AP) initiation (Kole and Stuart, 2012). Recently, it has
been shown that disturbing this subunit distribution in a mouse
model (Gabra2-1) can disrupt inhibitory control of excitation
and lead to seizures and early mortality (Hines et al., 2018).
Clearly, then, pyramidal neurons must precisely control the
allocation of GABAAR subtypes to specific subcellular sites.
The exact mechanisms by which this distribution is attained,
however, remain unclear. Previous work suggests that interactions between the a subunit and intracellular proteins may be a
determinant of GABAAR localization (Mukherjee et al., 2011;
Tretter et al., 2008; Tretter and Moss, 2008). Although the sequences of a subunits are largely homologous, there is a significant area of divergence in the intracellular domain (ICD) that lies
between transmembrane domains 3 and 4 (Olsen and Tobin,
1990). A 15–amino acid sequence within the ICD of a2 has
been shown in vitro to mediate preferential binding to the inhibitory synaptic protein collybistin (CB). Replacing this a2-specific
motif with the analogous sequence of a1 causes loss of a2containing synapses at the AIS, suggesting that CB may play a
role in the formation of subtype-specific inhibitory synapses via
its interaction with a2 (Hines et al., 2018).
CB is a guanine nucleotide exchange factor that activates the
small GTPase Cdc42, a regulator of the actin cytoskeleton. There
are a number of CB isoforms, but the protein is generally
composed of 3 domains: the pleckstrin homology (PH) phosphoinositide-binding domain, the catalytic RhoGEF (DH) domain, and
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Figure 1. The Gabra1-2 Mutation Alters the
Expression and Surface Stability of Specific
GABAAR Subtypes
(A) Cartoon showing the Gabra1-2 mutation, in
which amino acids 360-375 of the a1 subunit of the
GABAAR are replaced with that of the a2 subunit.
(B) Representative western blots examining
expression of key components of the inhibitory
synapse in total hippocampal lysates. GAPDH
served as a loading control.
(C) Pooled quantification (n = 5 biological and
technical replicates) reveals that the Gabra1-2
mutation leads to a decrease in the total expression of the a1 subunit, a trending decline in total a2
subunit expression (p = 0.077), and an increase in
total CB expression.
(D) Representative western blots from biotinylated
hippocampal slices examining the surface
expression of the a1 and a2 subunits. Total a1/2
subunit was normalized to GAPDH. Surface a1/2
subunit was normalized to pan-cadherin.
(E) Pooled quantification (n = 5 biological and
technical replicates) shows no change in the
surface:total ratio of the a1 subunit in Gabra1-2
mutants but reveals a significant decrease in the
surface expression of the a2 subunit.
Unpaired t tests with Welch’s correction used for
statistical analysis. (*p < 0.05; **p < 0.01). All data
are expressed as the percentage of WT and error
bars represent mean ± SEM.

the N-terminal Src-homology 3 (SH3) domain (Harvey et al., 2004;
Xiang et al., 2006). CB was first identified as a gephyrin-interacting protein (Kins et al., 2000). Gephyrin (GPN) is an integral
component of the inhibitory synapse that is known to bind directly
to a subunits of GABAARs, forming a submembrane scaffold that
anchors the receptors at the synapse (Mukherjee et al., 2011;
Tretter et al., 2008, 2012). CB binds GPN via the DH domain
and facilitates the aggregation and stabilization of GPN in the
submembrane space (Grosskreutz et al., 2001; Kins et al.,
2000; Tyagarajan et al., 2011). CB-knockout mice display a loss
of both GPN and GABAARs at postsynaptic structures in the
hippocampus (Papadopoulos et al., 2008, 2007), and mutations
in the human CB gene ARHGEF9 are associated with epileptic
diseases (Kalscheuer et al., 2009; Papadopoulos et al., 2015; Shimojima et al., 2011).
CB, therefore, is an attractive candidate for the regulation of
subtype-specific synapse formation, via preferential interactions
with the ICD of a2. However, no study has examined the association between CB and the a2 ICD motif in brain tissue or fully

assessed the effect that this association
has on the trafficking and stabilization
of a1- and a2-containing GABAARs at
synapses. To this end, we developed a
knockin mouse in which the CB binding
motif in the a2 loop is substituted into a1
(the Gabra1-2 mouse). We observed that
this mutation does indeed enhance the
association of the a1 subunit with CB in
brain lysate. The mutation also alters the
expression of a1, causes the enrichment of a1-GABAARs at
the AIS, and increases the size and density of a1-containing synapses in cultured hippocampal cells. In addition, the Gabra1-2
mutation alters both phasic inhibition in the CA1 and baseline
cortical electroencephalographic (EEG) activity, resulting in
resistance to kainate-induced seizures. To demonstrate the
strength of the seizure-resistant phenotype, we crossed
Gabra1-2 mice with Gabra2-1 seizure-prone mice and found
that the double heterozygous animals are spared from the
lethality observed in Gabra2-1 mutants.
RESULTS
The Creation of the Gabra1-2 Mutant Mouse
To probe the interaction between CB and the a2 ICD-binding
motif and determine its importance in synapse formation,
we generated a knockin mouse in which amino acids 360-375
of the a1 ICD were replaced by those of the a2 subunit (Figure 1A; Figure S1A). Mice were generated using homologous
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Figure 2. The Gabra1-2 Mutation Strengthens the Interactions
between the Chimeric a1-2 Subunit and CB
(A) Representative western blots showing co-immunoprecipitation levels of
CB and GPN with the WT and mutant a1 subunit.
(B) Pooled quantification (n = 4 biological and technical replicates) of protein
immunoprecipitation shows a significant reduction in the pull-down of the a1
subunit and significant increases in the pull-down of CB and GPN with the
chimeric a1-2 subunit. Total protein expression data were normalized to
GAPDH, and IP expression data were normalized to total a1 due to the
decrease in total a1 expression in Gabra1-2 mutants.
Unpaired t tests with Welch’s correction were used to analyze data (*p < 0.01;
**p < 0.05; #p < 0.005). Data are expressed as the percentage of WT and error
bars represent mean ± SEM.

recombination in ES cells (Genoway), as outlined previously
(Moore et al., 2018; Terunuma et al., 2014; Vien et al., 2015).
To confirm the Gabra1-2 mutation, we amplified the relevant
portion of genomic DNA from wild-type (WT) and homozygous
Gabra1-2 mice and sequenced the resulting PCR product,
confirming the insertion of the a2 amino acid sequence into
a1 (Figure S1B). Mice were genotyped by PCR using primers
that detected the a2 insertion (Figure S1C). Gabra1-2 homozygotes were viable and did not display any overt phenotypes.
Motor behavior, as measured by latency to fall off a rotarod
beam and the total distance traveled in the open field test,
was unaffected (Figure S2). In addition, cresyl violet staining
showed no differences in gross hippocampal anatomy between
WT and mutant animals (Figure S1D).
Changes in GABAAR Trafficking and Surface Stability in
the Gabra1-2 Mouse
Next, we investigated the effect the Gabra1-2 mutation has on the
expression and trafficking of inhibitory synapse components. To
this end, we immunoblotted total hippocampal lysates for the a1
and a2 subunits, GPN, CB, and synapsin (Figure 1B), as well as
the b3 and g2 subunits (Figure S1E). There were no changes
in the total expression of any of these proteins in heterozygous
Gabra1-2 mice compared with WT (data not shown). In homozygous animals, total levels of synapsin were unchanged, indicating
no widespread changes in synapse formation (Figure 1C). We
found that the total CB was increased in homozygous mutants
compared with controls, while GPN was unchanged (Figure 1C).
We found no changes in either b3 or g2 expression in homozygous animals compared to WT (Figure S1E). Immunoblotting
showed that the total a1 expression decreased in homozygous
Gabra1-2 mutants compared to controls, and total expression

672 Cell Reports 28, 670–681, July 16, 2019

of a2 also trended toward a decrease (Figure 1C). To examine
these findings in more depth, we performed surface biotinylation
experiments in WT and Gabra1-2 homozygous hippocampal
slices (Figure 1D). To better detect the low levels of surface a2
subunit, these experiments were performed using the previously
described pHlourin-a2 mice (Nakamura et al., 2016)—in which
the a2 subunit is GFP-tagged—crossed with Gabra1-2 animals.
We found that the ratio of surface to total protein for a1 was
unchanged, while that for the a2 subunit was reduced in mutants
compared with controls (Figure 1E), consistent with the decline in
total a2 expression (Figure 1C). Collectively, these results indicate a change in the trafficking of a subunits in Gabra1-2 mutants:
a2-containing GABAARs are displaced by a1-containing receptors accumulating in the plasma membrane. The data indicating
a depression in total a1 and a2 expression (Figure 1C) was obtained from crude hippocampal lysates, which contain the large
intracellular pool of a subunits. Thus, the reduction in the total
expression of a subunits may reflect a compensatory reduction
in the intracellular pool in response to additional plasma membrane accumulation of a1-GABAARs.
The Gabra1-2 Mutation Enhances the Interaction
between a1 and CB
It has been established that the a2 ICD motif mediates a preferential interaction with CB over GPN in vitro (Hines et al., 2018). To
confirm this finding in vivo, we performed co-immunoprecipitation (coIP) experiments on forebrain plasma membrane lysates
from WT and Gabra1-2 mice. Lysates were incubated with magnetic beads cross-linked to an N-terminal a1 antibody. Bound
material was eluted from the beads and subjected to SDSPAGE, followed by immunoblotting for either a1, CB, or GPN.
a1 immunoblots showed excellent purification of the subunit
from the total lysate and revealed reduced a1 in homozygotes,
in both the input and the immunoprecipitate (IP), consistent
with our earlier results (Figure 1C). Total and immunoprecipitated
CB levels, particularly the high molecular weight isoforms, were
increased in the Gabra1-2 IP compared with WT, confirming that
the a2 ICD motif does indeed mediate a preferential association
with CB in vivo (Figure 2). Interestingly, GPN levels were also
increased in the mutant IP compared with WT, indicating an
enhanced interaction between GPN and the mutant a1 subunit
(Figure 2). As it has been previously shown that GPN can bind
both a subunit ICDs and CB (Grosskreutz et al., 2001; Mukherjee
et al., 2011; Tyagarajan et al., 2011), these data suggest that,
via binding at the a2 ICD motif, GABAARs, CB, and GPN form
a synergistic tripartite complex in which strengthening the interaction between two partners enhances the stability of the entire
complex.
The Gabra1-2 Mutation Is Sufficient to Target a1Containing GABAARs to the AIS
Our previous work has demonstrated that the a2 ICD motif is
necessary for the accumulation of GABAARs at the AIS (Hines
et al., 2018). To determine if this motif is sufficient for the formation
of these precisely localized synapses, we performed immunocytochemistry (ICC) on WT and Gabra1-2 homozygous DIV21
hippocampal neurons. ICC was selected to allow for superior resolution of subcellular compartments, including the AIS. Neurons

Figure 3. The Gabra1-2 Mutation Induces
the Accumulation of Chimeric a1-2 Subunits
at Synapses in the Soma, Dendrites, and AIS
(A and C) Immunocytochemical (ICC) analysis of
the subcellular distribution of the a1 and a2 subunits of the GABAAR in WT and homozygous DIV21
hippocampal neurons. Neurons were stained with
antibodies against AIS markers (green) and either
a1 (A, red) or a2 (C, red). Insets show magnification
of representative AIS segments. White arrows
indicate synaptic clusters of mutant a1-2 on the
AIS.
(B) Pooled quantification (n = 3 biological and
technical replicates, N = 30 cells/genotype) of
puncta density, defined as the number of puncta
per 10 mm of neurite or soma, reveals that in
Gabra1-2 mutants, a1 puncta are significantly
denser and larger compared with WT in all
neuronal compartments examined.
(D) Pooled quantification (n = 3 biological and
technical replicates, N = 30 cells/genotype) demonstrates no change in the distribution of the a2
subunit in Gabra1-2 mutants compared to WT.
Scale bar, 10 mm (low mag); scale bar, 5 mm (AIS
inset).
Unpaired t tests were used to analyze data (*p <
0.0001). Error bars represent mean ± SEM.

were co-labeled with antibodies against AIS markers (pan-Na+
and ankyrin G, together) and either the GABAAR a1 or a2 subunit.
Imaging revealed a striking phenotype: chimeric a1-containing
GABAARs formed significantly denser and larger puncta on
Gabra1-2 AIS segments, compared with WT AIS segments (Figures 3A–3B). In addition, the number and size of synapses positive
for the a1 subunit was far larger in the somatodendritic compartments of mutant neurons (Figures 3A–3B). Experiments examining the localization of a2-containing GABAARs showed neither
changes in the levels of a2 at the mutant AIS nor alterations in
the density or size of a2 positive synaptic puncta (Figures 3C–
3D). These results indicate that the a2 360-375 motif does not
simply allow GABAARs to access and remain at the AIS, but it
also stabilizes receptors at synapses versus the extrasynaptic
space in the soma and dendrites, providing a mechanism for
the previously observed greater synaptic clustering of the a2
subunit (Tretter et al., 2008). This interpretation is strengthened
by data from a co-localization analysis performed on whole neurons showing that the co-localization of a1 puncta and the vesicular GABA transporter (VGAT, presynaptic marker), as measured

by the Pearson’s correlation coefficient,
was significantly increased in Gabra1-2
neurons (Figures S3A–S3B). In addition,
the co-localization of a1 puncta and GPN
puncta was significantly increased in
mutant neurons (Figures S3C–S3D). In
contrast, the Gabra1-2 mutation does not
affect the co-localization of a2 and VGAT
(Figures S4A–S4B).
To ensure that there were no gross
changes in inhibitory synapse formation,
neurons were co-labeled for AIS markers, GPN, and VGAT.
Co-localization between GPN and VGAT puncta was unchanged
by the Gabra1-2 mutation (Figures S4C–S4D). Further analysis
revealed a significant increase in the density and size of VGAT
puncta specifically in the soma and dendrites of Gabra1-2 neurons, with VGAT distribution at the AIS unchanged (Figure S5).
Analysis of GPN puncta showed the opposing effect: GPN
puncta at the AIS were significantly smaller and more numerous
in Gabra1-2 neurons when compared with WT controls, with no
changes in the soma and dendrites (Figure S6). These results
indicate that, in response to the increase in a1 positive synapses
on pyramidal neurons, only inhibitory interneurons contacting
the soma and dendrites create more presynaptic terminals.
The change in AIS GPN from the one or two large cartridges
seen in WT (Figure S6A) neurons to small, numerous puncta in
mutants suggests that increased stabilization of the chimeric
a1-GABAARs at the AIS requires a reconfiguration of the postsynaptic structure. To investigate this phenomenon further, neurons were labeled with antibodies against AIS markers and CB.
Unfortunately, CB staining produced a diffuse stain throughout
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Figure 4. Miniature Inhibitory Postsynaptic Currents (mIPSC) Kinetics Are Altered in the Gabra1-2 Hippocampus
(A) Representative mIPSC recordings from pyramidal neurons in the CA1 of WT and Gabra1-2 hippocampal slices, with superimposed spikes (right) representing
the average WT (black) and Gabra1-2 traces (red).
(B and C) Quantification of mIPSC kinetics (n = 6 mice/genotype in 3 cohorts) shows no effect of the mutation on mIPSC frequency (B), but (C) reveals a significant
decrease in the mIPSC decay time.
(D) Analysis of tonic inhibition in the CA1 (n = 8 mice/genotype in 4 cohorts) showed no difference between WT and homozygous animals. In-depth analysis of CA1
pyramidal neuron mIPSC amplitudes from WT and Gabra1-2 hippocampal slices (n = 6 mice/genotype in 3 cohorts) revealed a shift toward more high amplitude
events in Gabra1-2 mutants.

(legend continued on next page)
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Figure 5. The Gabra1-2 Mutation Produces
Baseline Abnormalities in Cortical Electroencephalographic (EEG) Recordings
(A) Spectrograms of representative WT and
Gabra1-2 (n = 9 mice/genotype in 3 cohorts) EEG
recordings without pharmacological manipulation.
(B) Power spectral density (PSD) plot of 10 minutes
of awake baseline EEG activity.
(C) Pooled quantification of the relative power of
binned frequency bands revealed a significant increase in the relative power of the a band (8–13 Hz)
in Gabra1-2 mutants compared with WT littermate
controls. Data were analyzed using unpaired t tests
(*p < 0.05). Error bars represent mean ± SEM.

the neuron, impeding analysis of any changes in the subcellular
distribution of CB (Figure S7).
Faster Mini Inhibitory Postsynaptic Current (mIPSC)
Decay Times and a Shift in mIPSC Amplitude
Distribution in Gabra1-2 Neurons
Our biochemical and immunostaining experiments revealed
changes in the expression and clustering of mutant a1-containing GABAARs, creating larger and denser inhibitory synapses. To
assess any effects these alterations could have on inhibitory synaptic signaling, we examined the kinetics of mIPSCs in CA1
pyramidal neurons (Figure 4A). The frequency of mIPSCs was
unaffected by the Gabra1-2 mutation (Figure 4B). mIPSC decay
times were significantly decreased in mutant neurons compared
with WTs (Figure 4C). Examination of tonic inhibition in the CA1
showed no changes between WT and homozygous mice (Figure 4D). While the average mIPSC amplitude was unchanged
(data not shown), further analysis showed that the Gabra1-2
mutation increased the proportion of high amplitude events (Figures 4E–4F). Fitting the data to Gaussian curves showed that the
mIPSC amplitude distribution in WT mice was best described by
the sum of 3 Gaussian components (Figure 4G); in Gabra1-2
mice, however, the mIPSC amplitude distribution was best
described as the sum of 4 Gaussian components, with the first
three similar in amplitude to the WT components and the fourth
consisting of a high amplitude component exclusive to Gabra1-2
mutants (Figure 4H). These data demonstrate that enhancing the
size and density of inhibitory synapses promotes inhibitory
neurotransmission.

Alterations in Baseline EEG Activity
in Gabra1-2 Mice
Gabra1-2 mice experience changes in the
distribution of subtype-specific GABAARs
and presynaptic inputs, as well as
enhanced inhibitory neurotransmission.
Given that inhibitory control of pyramidal
neurons is known to play an important role in the generation of
cortical oscillations measured by EEG (Buzsáki and Chrobak,
1995; Mann et al., 2005; Roux and Buzsáki, 2015), we assessed
baseline cortical EEG activity in WT and Gabra1-2 mice. Mice
were recorded for at least 1 hour of wakefulness one week
following EEG/electromyogram (EMG) implantation. Representative spectrograms and fast-Fourier transformation of 10 minutes
of this awake EEG activity showed changes in specific frequency
bands between WT and Gabra1-2 littermate controls (Figures
5A–5B). To examine these changes in more depth, we parsed
the EEG activity into the following frequency bands: d (1–4 Hz),
q (4–8 Hz), a (8–13 Hz), b (13–30 Hz), low g (30–50 Hz), and
high g (50–100 Hz). Comparison of the relative power of each
of these bands between WT and Gabra1-2 animals revealed a
significant elevation in the a range in mutants compared with
WT (Figure 5C).
Resistance to Kainate-Induced Seizures in Gabra1-2
Mice
Electrophysiological experiments show that inhibitory neurotransmission is changed in Gabra1-2 mice. To determine if these
physiological changes affect seizure susceptibility, known to be
at least partially dependent on inhibitory control of excitation
(Fritschy, 2008), we employed the kainate model. Kainate (KA,
20 mg/kg, i.p.) was administered to WT and homozygous adult
male littermates that were previously implanted with cortical
EEG and EMG monitors. Using the EEG and EMG data to determine the onset of epileptic activity and status epilepticus (SE)
(Figures 6A–C), we found that homozygous animals experienced

(E and F) The relative (E) and cumulative (F) frequency of mIPSC events of different amplitudes.
(G and H) Fitting the data to Gaussian curves and creating mIPSC histograms for WT (G) and Gabra1-2 (H) demonstrates the existence of a fourth, higher
amplitude (Peak 4, blue, mean = 80.7 pA) curve in mutants that does not exist in WT. This result indicates that a population of high amplitude mIPSCs occurs
exclusively in Gabra1-2 hippocampal slices.
Mann-Whitney tests were used to analyze mIPSC kinetics and tonic current data (#p < 0.05) and error bars represent mean ± SEM for these experiments. For (G)
and (H), data are expressed as mean ± SEM amplitudes (pA) for each of the Gaussian components used to obtain optimal fits to the data.
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Figure 6. The Gabra1-2 Mutation Confers Resilience to Kainate-Induced Seizures
(A) Representative EEG recordings and spectrograms from WT and Gabra1-2 mice injected with 20 mg/kg of kainate (n = 9 mice/genotype in 3 cohorts). The
beginning of the trace represents 30 s after the time of injection.
(B and C) Arrows indicate traces expanded in (B) for WT (black) and (C) for homozygote (red). For both (B) and (C), trace 1 (top) represents baseline activity shortly
after kainate injection, and trace 2 (bottom) represents the first tonic-clonic seizure.

(legend continued on next page)
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their first tonic-clonic seizure later than WT littermate controls
(Figure 6D). In addition, the latency to entering SE was longer
in homozygous mice (Figure 6E). Mutant animals also exhibited
resilience to SE-induced mortality: no homozygous animals
died in the two hours following KA injection, while about 40%
of WTs died during SE (Figure 6F). To explore the nature of
epileptic activity in Gabra1-2 animals further, we performed
fast-Fourier transformation on EEG recordings of SE and parsed
the recordings into the specific frequency bands outlined
above. This analysis revealed that Gabra1-2 mice experienced
a specific reduction in the relative power of the high g band
(50–100 Hz) during SE (Figures 6G–6H). Collectively, these
data show that the molecular and physiological changes induced
by the Gabra1-2 mutation provide resilience to KA-induced seizures by blunting high g power.
The Gabra1-2 Mutation Rescues Early Mortality in
Gabra2-1 Mice
Gabra2-1 mice possess a chimeric a2 subunit in which residues
360–375 from the a1 subunit have been knocked in to replace
the normal a2 ICD motif. This mutation leads to a loss of inhibitory synapses at the AIS. Both heterozygous and homozygous
Gabra2-1 pups display early mortality, with death peaking at
postnatal day 20 (PND20) due to spontaneous seizure activity
(Hines et al., 2018). To determine if the Gabra1-2 mutation
rescues the Gabra2-1 mortality phenotype, homozygous Gabra1-2 mice were crossed with homozygous Gabra2-1 mice.
The resulting offspring were genotyped by PCR with primers
that detected both the a1 and a2 insertions and were confirmed
to be heterozygous for both mutations (Figure 7A). Gabra2-1 heterozygous pups and Gabra1-2/Gabra2-1 double heterozygous
pups were monitored each day after birth until PND40. Of the
double heterozygous pups, 100% survived to PND40 compared
with only 61% of the Gabra2-1 heterozygous animals (Figure 7B),
demonstrating that the Gabra1-2 mutation and subsequent
phenotype can rescue early mortality in Gabra2-1 animals, likely
by promoting the synaptic localization of chimeric a1-GABAARs.
DISCUSSION
We have provided evidence that the a2 360-375 ICD motif mediates a preferential interaction with CB in vivo and that the presence of this motif in a given GABAAR is sufficient to stabilize
that receptor at the AIS. In addition, the a2 motif may constitute
an ‘‘inhibitory synaptic targeting’’ signal, generally enhancing the
anchoring of GABAARs in the synaptic space, as the Gabra1-2
mutation caused the accumulation of chimeric a1-GABAARs at

somatodendritic synapses, altering inhibitory neurotransmission
and baseline network oscillations. These changes were sufficient
to ameliorate the severity of kainate-induced seizure activity. The
Gabra1-2 mutation was also sufficient to rescue the lethal
seizure phenotype previously described in Gabra2-1 mice (Hines
et al., 2018).
Unexpectedly, given that recent in vitro data showed a relatively low affinity between GPN and the a2 ICD motif (Hines
et al., 2018), the Gabra1-2 mutation also led to an enhanced
in vivo interaction between the chimeric a1 subunit and GPN.
Previous work in Y2H systems has suggested that GPN, CB,
and the a2 subunit form a trimeric complex; interactions between GPN/a2 and CB/a2 were potentiated in the presence of
CB and GPN, respectively (Saiepour et al., 2010). In addition,
a2-GABAARs are more clustered at synapses than those containing a1, a phenomenon at least partially dependent on the
presence of GPN (Tretter et al., 2008). Our results support the
notion of a ‘‘tripartite complex’’ composed of GPN, CB, and an
a2 subunit, in which strengthening the interaction between two
of the complex’s partners stabilizes the entire trimer. GABAARs
are known to be initially inserted into the plasma membrane extrasynaptically (Bogdanov et al., 2006; Thomas et al., 2005); they
then laterally diffuse via Brownian motion until they contact scaffolding proteins in the synaptic space. These scaffolding proteins, including GPN (Jacob et al., 2005), contact the receptors,
slowing their diffusion rate and immobilizing receptors at the synapse (Choquet and Triller, 2013; Renner et al., 2008; Triller and
Choquet, 2005, 2008). Previous work has shown that the g2 subunit is necessary for the synaptic anchoring process (Alldred
et al., 2005); however, the g2 subunit is promiscuous and is an
unlikely candidate for GABAAR subtype-specific synaptic targeting. We demonstrate that a GPN-CB complex could act as a
subtype-selective structural anchor at the synapse, specifically
interacting with only those a subunits containing the a2 ICD
motif, creating a super-stable trimer that anchors the GABAAR
component at the synapse. The increased synaptic clustering
of mutant a1-GABAARs seen in the Gabra1-2 mouse is likely
due to increased recruitment of these receptors from the extrasynaptic space to the synapse via the a2 motif-CB-GPN interaction. In the AIS, where a2 is particularly enriched, the presence of
the trimeric complex would be especially important for the stabilization of a2-GABAARs. a1-GABAARs may be able to access the
AIS but will not stabilize as effectively at axo-axonic synapses
due to a1’s weaker interaction with CB. Other proteins that are
essential in AIS structure—including Ankyrin G and bIV-spectrin
(Susuki and Rasband, 2008)—may also interact with the trimeric
complex and/or the a2 ICD motif. Future research should

(D) The onset of the first tonic-clonic seizure event is delayed in Gabra1-2 mutants compared with WT littermate controls. The time of onset is displayed as a
percentage of WT.
(E) The onset of status epilepticus (SE) was delayed in Gabra1-2 mutants. Data are displayed as a percentage of WT littermate control.
(F) Kainate-induced mortality was reduced in Gabra1-2 animals compared with WT littermates. The survival plot shows the percentage of death of WT and mutant
mice at the corresponding time after kainate injection.
(G) PSD plot of the first hour of EEG activity after kainate injection.
(H) Pooled quantification of the relative power of binned frequency bands during 5 minutes of SE revealed a specific decrease in the contribution of high g band
(50–100 Hz) to total EEG power during SE in Gabra1-2 mutants.
Data from (D), (E), and (H) were analyzed with unpaired t tests (*p < 0.05). Data from (F) was analyzed with a log-rank (Mantel-Cox) test (*p < 0.05).Error bars
represent mean ± SEM.
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Figure 7. The Gabra1-2 Mutation Rescues the Gabra2-1 Lethal
Seizure Phenotype
(A) Genotyping for a Gabra1-2 homozygous (+/+) positive control, a Gabra2-1
homozygous (+/+) positive control, and two Gabra1-2/Gabra2-1 double heterozygous (+/) animals. Primers to detect the a1-2 and the a2-1 mutation
were used on both double heterozygotes.
(B) The Gabra1-2 mutation rescues the lethal seizure phenotype that leads
to early mortality in Gabra2-1 heterozygotes. Data are shown as a percentage
of Gabra2-1 and double heterozygous animals alive at a given time after birth
(n = 20 mice/genotype).

investigate potential interactions between the a2 subunit and
these AIS components and test the necessity of such interactions to the presence of GABAARs at the AIS.
In the chimeric Gabra1-2 mouse, a1-GABAARs containing the
a2 ICD motif acquire an ‘‘a2-like’’ pattern of distribution, with
greater synaptic clustering resulting in the proliferation of inhibitory synapses. Affected neurons undergo some compensation in
response to these changes: reducing total levels of a1 subunit
expression, increasing CB expression, and displacing surface
a2-GABAARs. Still, our data demonstrate that the Gabra1-2
mutation enhances inhibitory neurotransmission. Larger proportions of high-amplitude mIPSCs are a result of the significant
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increase in large, stable inhibitory synapses in Gabra1-2 neurons, while changes in decay kinetics likely reflect an alteration
in the type of GABAARs on the surface. Different a subunit compositions have been previously shown to affect mIPSC decay
time (Goldstein et al., 2002); an increase in the proportion of
a1-GABAARs at the synapse could shift the type of decay seen
in mIPSC recordings.
Interestingly, our data demonstrate that the alterations in inhibitory neurotransmission caused by the Gabra1-2 mutation perturb network activity and result in abnormal EEG activity at
baseline. Specifically, Gabra1-2 mice show an increase in the power of the a band. Inhibitory interneurons are thought to shape
neuronal oscillations (Klausberger and Somogyi, 2008), including
the a band (Lozano-Soldevilla, et al., 2014), and it is likely that the
constitutive Gabra1-2 mutation also affects interneurons themselves, as shown by the observed increase in VGAT positive presynaptic contacts onto mutant pyramidal neurons. The Gabra1-2
mutation may also affect the interplay between interneurons and
pyramidal neurons within neuronal networks. Either of these two
putative effects could cause changes in network synchrony.
Future research into the specific effect of the Gabra1-2 mutation
on interneurons, particularly experiments examining changes
in the types of interneurons contacting pyramidal cells, would
elucidate the mechanisms at play. Furthermore, in both humans
and mice the a frequency band is associated with behavioral inhibition, a process that underlies a variety of cognitive tasks,
including attention and working memory (Knyazev, 2007). In
addition, benzodiazepine sedation induces a decrease in a
band power (Hotz et al., 2000). Future research should examine
the possibility that Gabra1-2 mice may be resistant to the sedative effects of these GABAergic pharmacological agents and
may also perform better at tasks measuring behavioral inhibition,
such as the Go/No-Go task (Gubner et al., 2010).
While the mechanisms of ictogenesis remain unclear, it is
generally accepted that inhibitory control of excitation is a
contributing factor (Fritschy, 2008). In addition, AIS dysfunction
and mutations in the human CB gene ARHGEF9 are both linked
to epileptic disorders in humans (Buffington and Rasband, 2011;
de Groot et al., 2017; Kalscheuer et al., 2009; Shimojima et al.,
2011; Wimmer et al., 2010). The Gabra1-2 mutation enhances
inhibitory neurotransmission, resulting in a reduction in the
susceptibility of Gabra1-2 mice to kainate-induced seizures.
Intriguingly, neuronal activity during SE seems to be altered:
the Gabra1-2 mutation blunts the increase in g band power
commonly seen during SE (Sharma et al., 2018). Inhibitory interneurons are thought to shape neuronal oscillations, including
the g band (Mann et al., 2005; Wang et al., 2016), via synchronization of large pyramidal cell networks (Klausberger and Somogyi, 2008) and have been found to undergo morphological
and functional changes in animal models of epilepsy (Smith,
2014). The Gabra1-2 mutation may prevent or compensate
for KA-induced aberrant interneuron activity, thus mitigating
pathological neuronal synchronization, ameliorating SE severity,
and promoting survival. Interestingly, other genetic manipulations that affect GABAergic transmission have been shown
to blunt g power and SE severity in the same way as the
Gabra1-2 mutation (Moore et al., 2018), suggesting a possible
common pathway to reducing SE severity and mortality.

In the previously described Gabra2-1 mouse model, the ICD
motif of the a2 subunit is replaced with that of a1. Consistent
with the proposed importance of the a2 ICD motif in the stabilization of GABAARs at the AIS and elsewhere, Gabra2-1 animals lose both the majority of inhibitory synapses at the AIS
and inhibitory synapses that oppose parvalbumin positive inputs in the somatodendritic compartments. Gabra2-1 mice,
both heterozygous and homozygous, experience spontaneous seizures in the postnatal period, often leading to early
mortality around PND20 (Hines et al., 2018). Given that
the Gabra1-2 mutation seems to lead to the opposite effects
of the Gabra2-1 mutation, it is perhaps unsurprising that
crossing these two strains results in a rescue of the early mortality phenotype of Gabra2-1 animals. The restoration of inhibitory synapses at the AIS and the increase in size and density
of a1-containing synapses due to the Gabra1-2 mutation likely
compensates for the loss of a2-mediated inhibitory neurotransmission in Gabra2-1 mice. Importantly, the Gabra2-1 mutation reproduces the effects of many epileptogenic ARHGEF9
mutations in humans (Hines et al., 2018); the rescue of
Gabra2-1 by Gabra1-2 suggests that manipulating the distribution of a1-GABAARs or targeting the CB-GPN-a2 complex
could represent new avenues for research into therapies for
ARHGEF9-associated disorders.
Taken together, we report evidence of a preferential interaction in vivo between CB and the a2 ICD motif and show that
this interaction is sufficient to stabilize GABAARs at the AIS.
Our data support the theory of a trimeric CB-GPN-a2 subunit
complex at inhibitory synapse and present a possible explanation for the higher synaptic clustering of a2-GABAARs over
a1-GABAARs. These insights improve our understanding of the
subtype-specific inhibitory synaptogenesis that is so important
for normal brain function. Finally, Gabra1-2 mice are resilient to
kainate-induced seizures and rescue the ictogenic effects of
the Gabra2-1 mutation, revealing a new avenue of investigation
into treatments of epileptic disorders.
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Anti-GFP Antibody, Unconjugated chicken
polyclonal

Cell Signaling

Cat# 2555; RRID:AB_10692764

Anti-Sodium Channel, Pan antibody mouse
monoclonal

Sigma Aldrich

Cat# S8809; RRID:AB_477552

Anti-Synapsin 1 antibody mouse monoclonal

Synaptic Systems

Cat# 106 011; RRID:AB_2619772

Anti-VGAT antibody guinea pig polyclonal

Synaptic Systems

131 004; RRID:AB_887873

Donkey anti-mouse peroxidase conjugated

Jackson ImmunoResearch

Cat# 715-036-151; RRID:AB_2340774

Donkey anti-rabbit peroxidase conjugated

Jackson ImmunoResearch

Cat# 711-036-152; RRID:AB_2340590

Goat anti-guinea pig Alexa Fluor 647

ThermoFisher Scientific

Cat# A-21450; RRID:AB_2735091

Goat anti-mouse Alexa Fluor 488

ThermoFisher Scientific

Cat# A28175; RRID:AB_2536161

Goat anti-rabbit Alexa Fluor 568

ThermoFisher Scientific

Cat# A-11011; RRID:AB_143157

1 M CaCl2

Sigma Aldrich

Cat#: 21114

1 M KCl

Sigma Aldrich

Cat#: 60121

1 M MgCl2

Sigma Aldrich

Cat#: 63020

10x Phosphate Buffered Saline (PBS)

ThermoFisher Scientific

Cat#: BP399-4

32% PFA stock solution

Electron Miscroscopy Sciences

Cat#: 15714S

Acetic acid, glacial

ThermoFisher Scientific

Cat#: A38-212

Chemicals, Peptides, and Recombinant Proteins

Bovine Serum Albumin (BSA)

Sigma Aldrich

Cat#: A7906

Cresyl violet acetate

Sigma Aldrich

Cat#: C-5042

CsCl

Sigma Aldrich

Cat#: C4036

CsOH

Sigma Aldrich

Cat#: C8518

D-Glucose

Sigma Aldrich

Cat#: G8270

Dehydrated milk

Amazon

https://amazon.com/Emergency-EssentialsInstant-Nonfat-Milk/dp/B003SQ98EC

Ethanol, 200 proof

VWR

Cat#: 89125-172

Ethylene glycol-bis(2-aminoethylether)N,N,N0 ,N0 -tetraacetic acid (EGTA)

Sigma Aldrich

Cat#: E3889

Ethylenediaminetetraacetic acid (EDTA)

Sigma Aldrich

Cat#: E9884

EZ-Link Sulfo-NHS-SS-Biotin

ThermoFisher Scientific

Cat#: 21328T
(Continued on next page)
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Fisher Healthcare Tissue-Plus O.C.T. Compound

ThermoFisher Scientific

Cat#: 23-730-571

GABA

Sigma Aldrich

Cat#: A2129

GIBCO B27 (50x)

ThermoFisher Scientific

Cat#: 17504044

GIBCO GlutaMAX Supplement

ThermoFisher Scientific

Cat#: 35050061

GIBCO Penicillin/streptomycin (10,000 U/mL)

ThermoFisher Scientific

Cat#: 15140122

GIBCO Trypsin (2.5%), no phenol red

ThermoFisher Scientific

Cat#: 15090046

Glycine

VWR

Cat#: 0167

Invitrogen 1 M HEPES buffer solution

ThermoFisher Scientific

Cat #: 15630080

Invitrogen HBSS, 10X, no phenol red,
no calcium, no magnesium

ThermoFisher Scientific

Cat#: 14185-052

Invitrogen MES SDS Running Buffer 20x

Thermofisher Scientific

Cat#: NP0002

Invitrogen NuPAGE LDS Sample Buffer 4x

ThermoFisher Scientific

Cat#: NP0007

Invitrogen ProLong Gold Antifade Mounting
Reagent

Thermo Fisher Scientific

Cat#: P36930

Invitrogen Protein A Dynabeads

ThermoFisher Scientific

Cat#: 10001D

Isofluorane

Piramal Healthcare

Cat#: NDC 66794-013-25

Kainic Acid (Kainate)

Sigma Aldrich

Cat#: K0250

Kynurenic Acid

Sigma Aldrich

Cat#: K337

L-glutamine

Sigma Aldrich

Cat#: G8540

Laminin

Sigma Aldrich

Cat#: L2020

Mannitol

Sigma Aldrich

Cat#: M4125

Meglumine (NMDG)

Sigma Aldrich

Cat#: M9179

Methanol

Sigma Aldrich

Cat#: 179337

Mg-ATP

Sigma Aldrich

Cat#: A9187

MgSO4

Sigma Aldrich

Cat#: M3409

Na-ascorbate

Sigma Aldrich

Cat#: A7631

Na-GTP

Sigma Aldrich

Cat#: G8877

NaCl

Sigma Aldrich

Cat#: S7653

NaF

Sigma Aldrich

Cat#: S7920

NaH2PO4

Sigma Aldrich

Cat#: S9638

NaHCO3

Sigma Aldrich

Cat#: S6297

Neurobasal-A Medium, serum-free

ThermoFisher Scientific

Cat#: 10888022

Normal Goat Serum (NGS)

Abcam

Cat#: ab7481

Pierce Streptavidin Agarose beads

ThermoFisher Scientific

Cat#: 20347

Pierce BCA Protein Assay Kit

ThermoFisher Scientific

Cat#: 23225

Pierce ECL Western Blotting Substrate

ThermoFisher Scientific

Cat#: 32106

Poly-L-Lysine hydrobromide

Sigma Aldrich

Cat#: P1274

Roche cOmplete, Mini Protease Inhibitor
Cocktail

Sigma Aldrich

Cat#: 11836153001

Roche PhosSTOP

Sigma Aldrich

Cat#: 4906845001

Sodium orthovanadate

Sigma Aldrich

Cat#: 450243

Sodium pyruvate

Sigma Aldrich

Cat#: P3662

Sucrose

VWR

Cat#: 0335

Tetrodotoxin (TTX)

Tocris

Cat#: 1069

Thiourea

Sigma Aldrich

Cat#: 8658

Tris

VWR

Cat#: 0497

Triton X-100

Sigma Aldrich

Cat#: T8787
(Continued on next page)
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Tween-20

Sigma Aldrich

Cat#: P2287

b-mercaptoethanol

Sigma Aldrich

Cat#: 63689

Mouse: Gabra1-2(/) Mouse: Gabra1-2(+/)
Mouse: Gabra1-2(+/+)

This paper

N/A

Mouse: pHlourin-a2(+/+) Mouse: pHlourina2(+/+)/Gabra1-2(+/+)

Nakamura et al., 2016

N/A

Mouse: Gabra2-1(+/)/Gabra1-2(+/)

Hines et al., 2018; This paper

N/A

Gabra1-2 Genotyping Forward Primer: 50 -GGGTC
GACAACTATTTCACCAAGAGAGG-30

Integrated DNA Technologies

N/A

Gabra1-2 Genotyping Reverse Primer: 50 -GGGC
GGCCGCTTATCGGTCGATTTTGCTGACGC-30

Integrated DNA Technologies

N/A

Gabra1-2 Sequencing Primer 1: 50 -TGCCAGGGA
GTCTAACCGT-30

Integrated DNA Technologies

N/A

Gabra1-2 Sequencing Primer 2: 50 -CAAATAGCA
GCGGAAAGGCT-30

Integrated DNA Technologies

N/A

Gabra1-2 Sequencing Primer 3: 50 -CTGCCAGG
GAGTCTAACCGT-30

Integrated DNA Technologies

N/A

Gabra1-2 Sequencing Primer 4: 50 -GACAGTCG
GTCGATTTTGCTG-30

Integrated DNA Technologies

N/A

Experimental Models: Organisms/Strains

Oligonucleotides

Software and Algorithms
GraphPad Prism, v.7.01

GraphPad Software

RRID:SCR_002798 https://www.graphpad.com

Image Lab, v.5.0

Bio-Rad

RRID:SCR_014210 http://www.bio-rad.com

ImageJ v.2.0.0

Fiji

RRID:SCR_002285 https://imagej.net

LabChart v.7.3.8

AD Instruments

RRID:SCR_001620 https://www.adinstruments.
com/products/labchart

MetaMorph, v.7.8.0.0

Molecular Devices

RRID:SCR_002368 https://www.
moleculardevices.com

Mini-Analysis Software v.5.6.4

Synaptosoft

http://www.synaptosoft.com/MiniAnalysis/

MotorMonitor

Kinder Scientific

http://kinderscientific.com/products/open_field

NIS-Elements, v.4.20

Nikon

RRID:SCR_014329 https://www.microscope.
healthcare.nikon.com/products/software

pClamp v.10.3

Moleclular Devices

RRID:SCR_011323 https://www.
moleculardevices.com

Sirenia Acquisition, v.1.7.10

Pinnacle Technology

RRID:SCR_016183 https://www.pinnaclet.com

Axon Axopatch 200B Microelectrode Amplifier

Molecular Devices

Cat#: 200B https://www.moleculardevices.com/
sites/default/files/en/assets/data-sheets/dd/cns/
axon-axopatch-200b-microelectrode-amplifier.pdf

ChemiDoc XRS

Bio-Rad

Cat#: 1708265 http://www.bio-rad.com/en-uk/
product/chemidoc-xrs-system?ID=NINJHRKG4

Crytostat

ThermoFisher Scientific

Cat#: HM525 No longer available

Leica VT1000 S Vibrating blade microtome

Leica

Cat#: VT1000 S https://www.leicabiosystems.
com/histology-equipment/sliding-and-vibratingblade-microtomes/vibrating-blade-microtome/
products/leica-vt1000-s/

Nikon A1 confocal scanning laser microscope

Nikon

Cat#: A1HD25 https://www.microscope.
healthcare.nikon.com/products/confocalmicroscopes/a1hd25-a1rhd25

Nikon Eclipse E800 Brightfield Microscope

Nikon

No longer available

Other

e3 Cell Reports 28, 670–681.e1–e8, July 16, 2019

LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Stephen
J. Moss (Stephen.moss@tufts.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal Studies
Animals were cared for in accordance with the NIH Guide for the Care and Use of Laboratory Animals, and all protocols were
approved by the Institutional Animal Care and Use Committee (IACUC) of Tufts University School of Medicine. Gabra1-2 animals
were generated by Genoway (Lyon, France) and maintained in the vivarium at Tufts University’s Boston campus on a 12-hour
light/dark cycle with constant temperature and humidity. All animals except those that underwent EEG/EMG surgery were grouphoused and had access to food and water ad libitum, with once weekly cage changes. Germline transmission of the transgene
was detected using PCR with primers spanning the intronic region containing the remaining LoxP site. After founder Gabra1-2
mice were received from Genoway, mice were backcrossed onto the C57Bl6J line for at least 10 generations prior to experiments.
For all experiments, nontransgenic (wild-type, WT) littermates were used as controls. a2 surface expression experiments involved the
generation of a Gabra1-2/Myc-pHlourin-a2 (pHa2) double homozygote line. Gabra1-2 homozygotes and preexisting pHa2 homozygotes were bred for several generations until double homozygotes were born. In pHa2 animals, a pHlourin and Myc tag is incorporated into the N-terminal of the mature a2 subunit protein (Nakamura et al., 2016), allowing for better detection of low levels of a2
expression. In experiments involving the double homozygotes, WT/pHa2 littermates were used as controls. Rescue and survival
experiments involved the generation of Gabra1-2/Gabra2-1 heterozygotes, which was achieved by breeding Gabra1-2 homozygotes
and preexisting Gabra2-1 homozygotes (Hines et al., 2018) together. All experiments save cell culture immunocytochemistry (ICC)
and co-immunoprecipitation employed only male mice, aged 8-12 weeks. Co-immunoprecipitation experiments used age- and
sex-matched 8-12-week old male and female mice.
Cell Culture
Primary cultures of hippocampal neurons for ICC were prepared from monogenotype WT and homozygous Gabra1-2 litters.
Hippocampi from anaesthetized WT and Gabra1-2 P0 male and female neonates were dissected in ice-cold Hank’s buffered salt
solution (HBSS, ThermoFisher, #14185052) with 10 mM HEPES and subsequently pooled and incubated with 0.1% (v/v) trypsin
(ThermoFisher, #15090046) in HBSS for 20 minutes at 37 C. Cells were then washed one time with HBSS and triturated in fresh media
to dissociate neurons. After filtering with a 40 mm nylon mesh strainer (ThermoFisher, #22363547) to remove non-dissociated tissue,
resulting hippocampal neurons were counted on a hemocytometer and plated on poly-L-lysine (1 mg/mL, Sigma, #P1274)- and
laminin (1mg/mL, Sigma, #L2020)-coated glass coverslips in 35 mm dishes with 3 mL of Neurobasal-A culture medium
(ThermoFisher, #10888022) containing 2% B27 (v/v; ThermoFisher, #17504044), 1% penicillin/streptomycin (v/v; ThermoFisher,
#15140122), 0.6% D-glucose (w/v; Sigma, #G8270), and 1% GlutaMAX (v/v; ThermoFisher, #35050061) at a density of 5 3 105
cells/dish. Cells were grown at 37 C, 5% CO2 and 95% humidity, and allowed to mature for 21 days (Day in vitro 21, DIV21).
METHOD DETAILS
Cresyl violet staining
8-12-week-old male WT and Gabra1-2 mice were transcardially perfused with 30 mL of phosphate buffered saline (PBS, pH 7.4),
followed by 60 mL of 4% (v/v) paraformaldehyde in 0.15 M sodium phosphate buffer (PFA). Brains were post-fixed in PFA for 3 hours,
then washed in PBS and transferred to 30% sucrose solution for cryoprotection. Brains were embedded in optimal cutting temperature compound (ThermoFisher, #23730571) and frozen at 80 C. Brains were subsequently sliced on a cryostat (ThermoFisher,
#HM 525) into 40 mm sections and mounted onto gelatin-coated glass slides (Southern Biotech, #SLD01-CS). Mounted sections
were sequentially washed for 1 minute in (all v/v) 75% ethanol, 95% ethanol, 100% ethanol, distilled water, and then incubated in
filtered cresyl violet solution for 10 minutes (0.3% glacial acetic acid v/v, 0.5% cresyl violet acetate w/v). Staining was followed by
1-minute sequential washes in distilled water, 75% ethanol, 95% ethanol, 100% ethanol, and xylene. Images were acquired using
a Nikon E800 microscope (Nikon) with a 4x objective. 3 animals per genotype were imaged.
Western blotting
8-12-week-old male WT and Gabra1-2 mice were anaesthetized with isofluorane and their brains were rapidly removed. Whole
hippocampi were dissected out and mechanically homogenized with a 26G needle in ice-cold lysis buffer containing 5 mM EDTA,
5 mM EGTA, 1 mM sodium orthovanadate, 100 mM NaCl, 10 mM NaH2PO4, 25 mM NaF, 2% Triton-X (v/v), and protease (mini
cOmplete, Roche, #11836153001) and phosphatase inhibitor cocktails (PhosStop, Roche, #4906845001). Tissue was allowed to
lyse on a rotator for 30 minutes at 4 C. Samples were then centrifuged at 13,000rmp for 15 minutes at 4 C to pellet insoluble material.
Following lysis, protein concentration of the supernatant was assessed with a bicinchoninic acid (BCA) assay (Pierce, #23225)
and samples (50 mg) were boiled for 10 minutes at 70 C in NuPAGE LDS Sample Buffer (Invitrogen, #NP0007) containing 1% (v/v)
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b-mercaptoethanol. Samples were loaded onto NuPAGE 4%–12% Bis-Tris gels (Invitrogen, #NP0335) and run with MES SDS
running buffer (Invitrogen, #NP0002) at 100 V for 2 hours. After separation by SDS-PAGE, proteins were transferred to nitrocellulose
membranes using a wet transfer system (transfer buffer: 25 mM Tris, 192 mM glycine, 20% methanol) for 1 hour at 100 V. After
transfer, membranes were blocked in 5% milk in tris-buffered saline with 1% (v/v) Tween-20 (TBS-T) for 1 hour at room temperature.
Membranes were then incubated with their respective primary antibodies diluted into blocking solution overnight at 4 C (see Table S1
for antibody sources and concentrations). After 3 washes in TBS-T, membranes were probed with HRP-conjugated secondary
antibodies diluted into blocking solution (1:5000, Jackson ImmunoResearch Laboratories, see Table S1 for complete list) for
1 hour at room temperature. Blots were washed 3 times in TBS-T and developed with a chemiluminescence system as per manufacturer’s instructions (Pierce ECL, ThermoFisher, #32106). Blots were imaged (ChemiDoc XRS, Bio-Rad; paired with Image Lab 5.0,
Bio-rad) and band densitometry was measured with ImageJ v.2.0.0 (NIH). For quantification, specific protein levels were determined
by normalizing to GAPDH loading control densitometry results. Gabra1-2 protein levels were normalized to WT control (100%).
5 independent experiments were performed for all western blotting experiments. Unpaired t tests with Welch’s correction were
performed on GraphPad Prism v.7.01 to compare mean values between WT and Gabra1-2, with values below *p < 0.05 considered
significant. Graphs were plotted as mean ± standard error of the mean (SEM).
Biotinylation of cell surface proteins
8-12-week-old male mice of all genotypes (WT and Gabra1-2 homozygous for a1; pHa2 and pHa2/Gabra1-2 homozygous for a2)
were anaesthetized with isofluorane and their brains were rapidly removed. 350 mm-thick coronal hippocampal slices were prepared and sectioned on a vibratome (Leica VT1000S) in ice-cold cutting solution containing 87 mM NaCl, 2.5 mM KCl, 0.5 mM
CaCl2, 25 mM, NaHCO3, 1.25 mM NaH2PO4, 7 mM MgCl2, 50 mM sucrose, and 25 mM glucose. After sectioning, slices were
allowed a 1-hour recovery period in 32 C artificial cerebrospinal fluid (aCSF) containing 126 mM NaCl, 26 mM NaHCO3,
2.5 mM KCl, 2 mM MgCl2, 2 mM CaCl2, 1mM glutamine, 1.25 mM NaH2PO4, 1.5 mM sodium pyruvate, and 10 mM glucose.
Following recovery, slices were incubated for 45 minutes in ice-cold, 1 mg/mL EZ-Link Sulfo-NHS-SS-biotin (ThermoFisher,
#21328T) in aCSF. All solutions described above were oxygenated with 95% (v/v) O2/5% (v/v) CO2. After 3 rinses in ice-cold
100 mM glycine in aSCF to halt the biotin reaction and 2 washes in ice-cold plain aCSF, samples were mechanically homogenized
with a 26G needle and lysed in the previously described lysis buffer. Lysis was carried out as described above. After adjusting for
protein concentration measured by BCA assay, hippocampal lysates (500 mg) were incubated with 50 mL of Strepavidin Agarose
beads (ThermoFisher, #20347) on a rotator at 4 C overnight, with a portion (50 mg) reserved for total protein analysis. The supernatant was removed, and beads were washed in lysis buffer 3 times. All samples were mixed with NuPAGE LDS Sample Buffer
(Invitrogen, #NP0007)/1% (v/v) b-mercaptoethanol. Samples were then boiled for 10 minutes at 70 C. Bound proteins and total
protein samples were subjected to SDS and immunoblotting (see Table S1 for antibody sources and concentrations), developed,
and imaged as described above. Band densitometry was measured with ImageJ v.2.0.0 (NIH) and protein levels were determined
by normalizing to GAPDH (total protein) and/or pan-cadherin (surface protein) loading controls. The ratio of surface protein:total
protein was calculated, and Gabra1-2 values were normalized to WT or pHa2 control (100%). 5 independent experiments were
performed for all biotinylation experiments. Unpaired t tests with Welch’s correction were performed on GraphPad Prism
v.7.10 to compare mean values between WT and Gabra1-2 or pHa2 and Gabra1-2/pHa2, with data below p < 0.05 considered
significant. Graphs were plotted as mean ± SEM.
Co-Immunoprecipiation (coIP)
Forebrains (cortex and hippocampus) were rapidly removed from isofluorane-anaesthetized 8-12-week-old male and female WT and
Gabra1-2 mice and collected in an ice-cold cryoprotectant buffer (225 mM mannitol, 75 mM sucrose, 30 mM Tris-HCl, pH 7.4). Tissue
was mechanically homogenized using 14 strokes of a dounce homogenizer in homogenization buffer (225 mM mannitol, 75 mM
sucrose, 0.5% (w/v) BSA, 0.5 mM EGTA, 30 mM Tris-HCl, pH 7.4) and subjected to the following sequential centrifugation, all at
4 C: two 5-minute spins at 800 x g to remove unbroken cells; two 10-minute spins at 10,000 x g to remove mitochondria; and
two 20-minute spins at 25,000 x g to isolate plasma membrane (PM) fractions. PM fractions were re-suspended and lysed in a lysis
buffer containing 150 mM NaCl, 10 mM Tris, 0.5% Triton-X, and protease and phosphatase inhibitor cocktails, as above. These PM
lysates (5000 mg protein) were incubated with 150 mL Protein A Dynabeads (ThermoFisher, #10001D) cross-linked to 15 mg of
N-terminal a1 antibody (Abcam, #ab33299) overnight at 4 C. Supernatant was removed, and beads were washed 3 times in PBS
with 0.05% (v/v) Tween. All samples were eluted in SDS-PAGE sample buffer. Immunoprecipitation samples were first boiled at
55 C for 10 minutes to remove protein complexes from the beads, and then both total lysate and immunoprecipitation samples
were boiled at 95 C for 5 minutes. Samples were run through SDS-PAGE and western blotting for the appropriate proteins and developed and imaged as detailed above (see Table S1 for antibody sources and concentrations). For quantification using ImageJ v.2.0.0
(NIH), relative immunoprecipitation levels were determined by first normalizing to a1 densitometry results to account for differences in
the amount of a1 present in WT versus Gabra1-2 samples. Gabra1-2 protein levels were then normalized to WT control (100%).
4 independent experiments were performed for the coIP experiments. Unpaired t tests with Welch’s correction were performed
on GraphPad Prism v.7.10 to compare mean values between WT and Gabra1-2, with data below p < 0.05 considered significant.
Graphs were plotted as mean ± SEM.
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Immunocytochemistry (ICC)
DIV21 primary hippocampal WT and Gabra1-2 cells were washed once in PBS and fixed for 20 minutes in a solution of 4% (w/v)
sucrose and 4% (v/v) paraformaldehyde in PBS. After 3 PBS washes to remove fixative, cells were blocked in a solution containing
5% (w/v) bovine serum albumin (BSA) for 1 hour at room temperature. Cells were then incubated with the appropriate primary antibodies (see Table S1 for details) diluted into a modified blocking solution containing 2.5% (w/v) BSA, 2% (v/v) normal goat serum
(NGS), and 0.1% (v/v) Triton-X for 2 hours at room temperature. After 10 washes in PBS to remove unbound antibody, cells were
incubated with Alexa conjugated secondary antibodies (1:5000, ThermoFisher, see Table S1 for details) in modified blocking solution
for 1 hour at room temperature. Cells were washed with PBS 10 times and mounted on glass slides (Electron Microscopy Sciences,
#71864) using ProLong Gold Antifade mounting media (ThermoFisher, #P36930).
Images were acquired with a Nikon A1 confocal scanning laser microscope coupled with NIS Elements software v.4.20 (Nikon).
Images were taken at a 512 3 512 resolution (17 nm/pixel) with a 60x (oil, numerical aperture: 1.00) objective, with the imager blind
to genotype. Settings were optimized to ensure low background and sufficient signal/noise ratio, and within experiments settings
were unchanged between genotypes. Images were saved as single-channel and overlay 8-bit TIF-files. Immunostaining density
(the number of puncta per 10 mm of neurite/soma) and area were quantified using MetaMorph software (Molecular Devices). For definition of image thresholds, the brightness of single-channel images was adjusted with the ‘‘inclusive thresholding’’ function. Within
each experiment, threshold adjustments were unchanged between genotypes. Puncta number and size was assessed using the
MetaMorph-based ‘‘Integrated Morphometry Analysis’’ tool, which calculated the number, area, and average intensity of single
objects > 0.05 mm. Co-localization analysis (calculation of the Pearson’s correlation coefficient) between single-channel images
was achieved with the Coloc2 macro on ImageJ v.2.0.0/Fiji (https://imagej.net/ImageJ). A region of interest (ROI) containing both
the soma and neurites of each neuron was defined on 1 channel using the polygon drawing tool and transferred to the other channel.
Background was subtracted using a Rolling-Ball Background Subtraction of 50. All analysis was performed blinded to genotype.
3 independent experiments were performed for each antibody combination and within each experiment 10 neurons were imaged
and analyzed per genotype. Results were analyzed on GraphPad Prism v.7.10 with unpaired t tests to compare mean values between
WT and Gabra1-2, with data below p < 0.05 considered significant. Graphs were plotted as the mean ± SEM.
Electrophysiology
Brain slices were prepared from 4-6-week-old WT and Gabra1-2 male, isofluorane-anaethetized mice. 300 mm sections were cut in
ice-cold, oxygentated saline (92 mM NMDG, 2.5 mM KCl, 1.25 mM NaH2PO4, 30 mM NaHCO3, 20 mM HEPES, 25 mM glucose, 2 mM
thiourea, 5 mM Na-ascorbate, 3 mM Na-pyruvate, 0.5 mM CaCl2, 10 mM MgSO4) using a vibratome (VT1000S, Leica), then incubated
at 32 C for 10 minutes in holding aSCF (92 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 30 mM NaHCO3, 20 mM HEPES, 25 mM
glucose, 2 mM thiourea, 5 mM Na-ascorbate, 3 mM Na-pyruvate, 2 mM CaCl2, 2 mM MgSO4). Brain slices were then transferred
to the recording chamber and were continually perfused with normal aCSF (126 mM NaCl, 2.5 mM KCl, 2 mM CaCl2, 2 mM
MgCl2, 26 mM NaHCO3, 1.25 mM NaH2PO4, 10 mM glucose, 1.5 mM Na-pyruvate, 1 mM glutamine, 3 mM kynurenic acid,
0.005 M GABA) at 32 C. All solutions were bubbled with 95% (v/v) O2/5% (v/v) CO2. Patch pipettes (5-7 MU) were pulled from
borosilicate glass (World Precision Instruments) and filled with intracellular solution (140 mM CsCl, 1 mM MgCl2, 0.1 mM EGTA,
10 mM HEPES, 2 mM Mg-ATP, 4 mM NaCl, 0.3 mM Na-GTP, pH to 7.2 with CsOH). To examine mini inhibitory postsynaptic currents
(mIPSCs), tetrodotoxin (TTX; 0.5 mM) was added to the aCSF. A 5-minute stabilization period was allowed after obtaining the wholecell recording conformation (holding potential of 60 mV) in the hippocampal CA1. Subsequently, currents were recorded using an
Axopatch 200B amplifier (Molecular Devices), low-pass filtered at 2 kHz, digitized at 20 kHz (Digidata 1440A; Molecular Devices), and
stored for offline analysis. Series resistance and whole-cell capacitance were continually monitored and compensated for throughout
the course of the experiment. Recordings were eliminated from data analysis if series resistance increased by > 20%. mIPSCs were
analyzed using mini-analysis software v.5.6.4 (Synaptosoft). Minimum threshold detection was set to 3x the value of baseline noise
signal. To assess mIPSC kinetics, the recording trace was visually inspected and only events with a stable baseline, sharp rising
phase, and single peak were used to negate artifacts from event summation. Only recordings with a minimum of 200 events fitting
these criteria were analyzed. mIPSC amplitude and frequency from each experimental condition were pooled and expressed as
mean ± SEM. To measure mIPSC decay, we averaged 100 consecutive events, fit the decay to a double exponential, and
took the weight decay constant (s). Statistical analysis for mean mIPSC kinetics was performed using a Mann-Whitney test, where
p < 0.05 is considered significant. To display the distribution of mIPSC amplitudes, data was fitted with a Gaussian function:
.
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Where A is the amplitude, m is the Gaussian mean amplitude current, s the Gaussian standard deviation, and C is the constant for
each component i.
For tonic current measurements in the CA1, once the response reached a plateau level an all-points histogram was plotted for a
10 s period before and during 100 mM picrotoxin application. Recordings with unstable baselines were discarded. Fitting the
histogram with a Gaussian distribution gave the mean baseline current amplitude. The difference between the amplitudes before
and during picrotoxin application was considered to be the tonic current. The negative section of the all-points histogram which
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corresponds to the inward IPSCs was not fitted with a Gaussian distribution (Kretschmannova et al., 2013; Nusser and Mody, 2002).
Tonic current was analyzed with a Student’s t test, where p < 0.05 is considered significant.
Motor behavior
Genotype-blinded behavioral testing was performed on group-housed 8-12-week-old male WT and Gabra1-2 mice. All behavioral
testing occurred during the light phase between 9am and 4pm, following at least 1 hour of habituation to the temperature controlled
(70-74 C) behavioral testing facility. Littermates were used for all experiments. Protocols for all testing were based on standard
protocols. Equipment was cleaned between each mouse using 70% ethanol followed by Clidox (chlorine dioxide based sterilant).
For assessment of motor behavior, the rotarod test and open field test (OFT) were employed. During the rotatrod test, mice were
placed on the rotarod apparatus (Med Associates; rubber-coated cylinder 4 cm in diameter, fixed 30 cm above ground) and trained in
the task in three 3-minute trials at a speed of 16 rotations per minute (rpm), with a 15-minute inter-trial interval. After completion of
training, the animals were returned to their homecage and allowed to recover for an additional 15 minutes before testing began.
Rotarod testing was conducted on an accelerated speed setting, with rotarod speeds increasing from 4 to 40 rpm over the course
of 5 minutes. Animals were subject to three 5-minute-maximum tests, again with an inter-trial interval of 15 minutes. The latency to fall
off the rotarod beam or to lose control (defined as 3 rotations around the cylinder without active movement) was measured for each
test, and the average latency was calculated for each animal.
In the OFT, mice were individually placed in the center of a 60 cm x 60 cm white-walled box and allowed to freely explore for
10 minutes. The OFT box was positioned inside a photobeam frame with 16 3 16 equally spaced photo emitters and detectors
(Kinder Scientific). The frames connected to MotorMonitor software (Kinder Scientific), which measured the total distance traveled
for each mouse. All behavioral tests used 10 mice per genotype in at least 3 independent cohorts. All results were analyzed on
GraphPad Prism v.7.10 with one-way analysis of variance (ANOVA), with posthoc testing comparing the means between WT and
Gabra1-2 hetero- and homozygotes. Data below p < 0.05 was considered significant. Graphs were plotted as mean ± SEM.
Electroencephalography (EEG)
Surgery and recording
8-12-week-old male WT and Gabra1-2 littermates were used for EEG studies. Prefabricated EEG and electromyography (EMG)
headmounts (2-channel, Pinnacle Technology, #8201) were implanted under isofluorane anesthesia (3%–5% for induction,
1%–2% for maintenance). Mice were given 0.1 mg/kg buprenorphine i.p. as an additional analgesic. All surgical instruments were
heat-sterilized. The fur covering the scalp was shaved off and the scalp itself was sterilized with 3 applications of b-iodine, with a
wash of 70% ethanol between each application. Scissors were used to make an incision down the vertical midline of the scalp to
expose the skull. The skull was then washed with a sterile Q-tip soaked in 70% ethanol. The EEG/EMG headmount was aligned
with lambda and secured to the skull with two 0.10 inch and two 0.12-inch ground screws (Pinnacle Technology, #8209 and
#8212, respectively). Two of the screws served as EEG leads in the frontal cortex, 1 as a reference ground, and 1 as an animal ground.
Dental cement was used to close the scalp and secure the headmount. Mice were singly-housed post-surgery. After a minimum of
7 days of recovery, EEG and EMG recordings were collected with Sirenia Acquisition software v.1.7.10 (Pinnacle Technology).
Recordings were performed in awake, behaving WT and Gabra1-2 mice. Animals were given 1 hour of habituation to the recording
chamber and the preamplifier. For baseline EEG activity, EEG/EMG recordings were then collected for 2 hours. For epileptic EEG
activity, EEG/EMG recordings were collected for 1 hour pre- and 2 hours post-injection of the chemoconvulsant kainic acid (KA;
20 mg/kg i.p.; Sigma, #K0250). All recordings were processed and analyzed blind with pClamp v.10.3 (Molecular Devices) and
Labchart v.7.3.8 (AD Instruments) software.
Baseline analysis
Power analysis was performed using LabChart software v.7.3.8. Fast-Fourier transform (FFT) was used to transform 10 minutes of
awake baseline activity from the time domain to the frequency domain to generate a power spectral density plot (FFT size 4K, 93.7%
overlap, Hanns window function). Activity was then binned into the following frequency bands: delta (1-4 Hz), theta (4-8 Hz), alpha
(8-13 Hz), beta (13-30 Hz), low gamma (30-50 Hz), and high gamma (50-100 Hz). 9 animals per genotype were used in at least 3
separate cohorts. The power of each frequency band was expressed as a percentage of the total EEG power and plotted as
the mean ± SEM. Unpaired t tests were performed with GraphPad Prism v.7.10 to compare genotype means, and data below
p < 0.05 was considered significant.
Seizure analysis
The latency to the first seizure event and the latency to the onset of status epilepticus (SE) was measured with pClamp software
v.10.3. Epileptiform activity was defined as having an amplitude of at least 2.5x the standard deviation of baseline activity and lasting
for at least 30 s. Latency to the first seizure was defined as the time from KA injection to the start of the first detected electrographic
seizure. SE was defined as continuous epileptiform activity lasting at least 5 minutes, with no more than 30 s between epileptiform
events. Latency to SE was defined as the time from KA injection to the start of the first period of such activity. As above, FFT was used
to transform the first hour after KA injection from the time domain to the frequency domain to generate a power spectral density plot
(FFT size 4K, 93.7% overlap, Hanns window function). Activity was then binned into the same frequency bands as above. Mortality
during the post-KA period was also assessed. 9 animals per genotype were used in at least 3 separate cohorts. Gabra1-2 data
(latency to first seizure and latency to SE) was normalized to WT littermate controls to account for variability due to differences
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in KA potency between cohorts. Results were analyzed with GraphPad Prism v.7.10 using either unpaired t tests or unpaired t tests
with Welch’s correction, where appropriate, to compare mean values between WT and Gabra1-2. Graphs were plotted as the
mean ± SEM. Mortality data was plotted as a survival curve and analyzed with a log-rank (Mantel-Cox) test. Data below p < 0.05
was considered significant.
Survival assessments
Assessment of postnatal survival comparing Gabra2-1 heterozygotes and Gabra1-2/Gabra2-1 heterozygotes was performed. Litters
were observed by the investigator once per day until weaning at postnatal day 21 (PND21) to check for pup death. After weaning,
offspring were observed once per day to check for mortality until PND40. At least 20 pups per condition were assessed. Results
were plotted with GraphPad Prism v.7.10 as the percent of animals alive from PND0-PND40.
QUANTIFICATION AND STATISTICAL ANALYSIS
All programs used for quantification and statistical analysis are outlined in the Method Details section. Statistical analyses are
described in the corresponding figure legends and also in the Method Details section.
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